Norsk
KEY FIGURES
179
new ideas (dofier)
10
BILLION NOK COMBINED VALUE
OF PORTFOLIO COMPANIES
26
NEW LICENSE AGREEMENTS
104
NEW PATENT APPLICATIONS
163
NEW CLINICAL STUDIES
433
ONGOING CLINICAL STUDIES
5
NEW COMPANIES ESTABLISHED
60
MILLION NOK TO
NEW RESEARCH
201
MILLION NOK IN
PRIVATE CAPITAL RAISED
Innovation
PHOTO: Festoon Lighting Brisbane
– how do you take your research to market?
Inven2’s main area of focus is taking research results and turning them into a product or service in a market. This is done through a value chain that starts with idea hunting and marketing of Inven2’s services aimed at researchers at the University of Oslo and Oslo University Hospital.
Read more
Innovation activities
Each year, Inven2 organises a wealth of activities intended to stimulate innovation. We hold some activities independently, but many take place in cooperation with players involved in the big ecosystem we are part of.
Industry collaboration
for innovation
Collaboration between business and research is important to achieving more innovation and leads to more commercialisations. Inven2 has made targeted efforts on industry collaboration for close to two years through a number of different projects.
Read more
Copyright GE Healthcare 2019, with permission to be used by ImTECH
IMTECH
Spearhead in diagnostic imaging
Oslo ImTECH is ambitious about becoming one of the leading centres in the development of diagnostic imaging and image processing used in hospitals worldwide. This technology is an essential part of giving patients the best treatment possible.
More about Imtech
CLINICAL TRIALS ARE THE KEY TO MEDICAL DEVELOPMENT
Clinical trials involve testing new drugs and medical equipment on human subjects. Clinical trials can be conducted on both healthy volunteers and patients.
Read moreA word from the CEO
Ten billion and growing
The year 2018 has been a particularly eventful year for Inven2. We have had a high level of activity and achieved many of our objectives of taking research results and turning them into products or services in the market.
If there is one thing I would like to highlight as particularly pleasing, it is that many of the companies we have established are doing very well in fierce global competition. Our portfolio of innovative businesses was worth NOK 10 billion at the turn of the year.
Read moreAbout inven2
Making a difference by transforming knowledge into products and services for the benefit of society.
Research and knowledge are the keys to addressing global challenges relating to health, climate and the environment. Highly capable researchers and clinicians from larger parts Norway report their ideas and discoveries to us. We develop and manage these ideas, and proceed with the ones that can be transformed into products that benefit society.
We have started businesses that develop better cancer therapies, combat antibiotic resistance and identify security breaches in complex IT systems. Two-thirds of our businesses and licences are in the field of life science, since the scientific community we represent is particularly strong in that field.
Another important area for us is to administer agreements on clinical trials on behalf of the hospitals in our region and in the northern part of Norway. We make active endeavours to get more international companies to carry out their clinical trials in Norway. That way, more innovative treatment can benefit more patients in Norway.
Inven2 is a limited company owned by the University of Oslo and Oslo University Hospital. Inven2 currently has 34 employees.
CUTTING EDGE 2018
We are proud to co-organise the Cutting Edge Festival, Norway’s biggest science and technology event, where we present the latest in science, technology and innovation together with our partners Oslotech and the University of Oslo.
www.cuttingedgefestival.no Watch film from Cutting EdgeCUTTING EDGE FESTIVAL IN NUMBERS
1000
VISITORS
73
TALKES
3
WORKSHOPS
5
DEBATES
88
MEETINGS
51
EXHIBITORS
USEFUL AND IMPORTANT MATCMAKING AT CUTTING EDGE
Almost 90 1:1 meetings between researchers, mature companies and start-ups were held at this year’s Cutting Edge. ‘We received important feedback,’ says researcher Henriette Andresen after her meeting with Pfizer.
Read morePortfolio businesses
Inven2’s portfolio currently comprises 45 companies, and five new ones were established in 2018. Together, the companies are worth around NOK 10 billion, and their value is growing. You can read more about the companies Vaccibody, Meshcrafts and Catalysts below.
Eduardo Bravo, who has broad international experience, was appointed new CEO of Nordic Nanovector in 2018. The company is now working on a registration trial for its lymphoma treatment.
If everything goes according to plan, this treatment developed in Norway will be on the market in 2020. Ultimovacs is another company developing cancer treatment. In 2018, the company acquired the technology segment of a Swedish company for over NOK 50 million, and testing of its therapeutic cancer vaccine is now well under way in the USA. The company is currently planning to become listed on the stock exchange. Last, but not least, is the company Zelluna Immunotherapy. They are developing a cancer treatment based on a type of immunotherapy called TCR, in which what are known as super T-cells are injected into cancer patients so that the immune system itself finds and kills the cancerous cells.
Portfolio
Beep Systems AS
cFIRE AS
Chielstad AS
Corall Studio AS
Crowdo AS
Dronebud AS
Nomademat AS
Safenode AS
SERCA Pharmaceuticals AS
SporTech AS
Products
Inven2 want to make a difference by transforming research and knowledge into products and services for the benefit of society. We have contributed to the launching of many products and services. Here is a selection.
Ecosystem
Inven2 is part of a vital, ever-growing ecosystem in research and development. The area near Inven2’s premises in Oslo Science Park is home to a number of clusters and incubators, as well as the University of Oslo and Oslo University Hospital.
Read moreOrganisation
